All In Biotech

Drug Trial Radar · NCT07221370

Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients

Last checked: Nov 20, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 176 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

176

Planned (sponsor's estimate)

Start

Oct 21, 2024

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Riverside University Health System Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to determine if oral vancomycin can prevent C.diff infection in adults who are critically ill and are at high risk of C.diff infection due to their medical conditions and being in the hospital. It will also help us learn about the safety of the drug in this setting. The main questions the trial aims to answer are: * Does oral vancomycin lower the rate of C.diff infection in high-risk patients? * Does C.diff carrier status change the C.diff infection rate as well as clearance of carrier status when vancomycin is used as primary prophylaxis? Researchers will compare the oral, active drug vancomycin to a placebo (a look-alike substance that contains no drug) to determine if vancomycin works to prevent C.diff infection in the hospital. Participants will: * Take oral vancomycin or a placebo while they receive systemic antibiotic(s) for up to five days after the last dose of said systemic antibiotic(s). The treatment of said systemic antibiotic(s) is not to exceed 21 days. * When discharged from the hospital, participants will continue to take the study medication in the event he/she did not complete the intended course of the study medication while in the hospital. * Participants will provide stool sample or rectal swabs for to assess their C.diff carrier status as well as any change in stool microbiome status, including VRE (vancomycin resistant Enterococcus) * After completion of the intervention period, participants will be contacted via telephone to assess if they developed diarrhea or any untoward effects of study medication.

Conditions

  • Clostridium Difficile Infection
  • Vancomycin Resistant Enterococci Infection

Interventions

  • Vancomycin 125mgDrug

    Vancomycin 125 mg orally daily

  • PlaceboDrug

    Syrup solution used to mixed with Vancomycin will be used in equal volume to be the placebo comparator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence the rate of healthcare facility-onset Clostridioides dificile infection (CDFO-CFI).Time frame: up to 4 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Riverside University Health System

    Moreno Valley, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.